<DOC>
	<DOCNO>NCT00736619</DOCNO>
	<brief_summary>For patient type cancer , one standard treatment option cetuximab ( Erbitux® ) + radiation . We wish study addition albumin-bound paclitaxel ( Abraxane® ) standard regimen cetuximab + radiation . Albumin-bound paclitaxel cetuximab chemotherapy drug administer vein . Previous study show albumin-bound paclitaxel kill head neck cancer cell give alone combination chemotherapy . The purpose study establish safe dose range albumin-bound paclitaxel give combination cetuximab radiation therapy . The investigator want find effect , good and/or bad , albumin-bound paclitaxel head neck cancer .</brief_summary>
	<brief_title>Weekly Nanoparticle Albumin-Bound Paclitaxel ( Abraxane ) + Weekly Cetuximab + Radiation Therapy ( IMRT , Intensity-Modulated Radiation Therapy ) Patients With Stage III-IVB Head Neck Squamous Cell Carcinoma ( HNSCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Locally and/or regionally advanced head neck squamous cell carcinoma ( AJCC Stage IIIIVB ) Karnofsky performance status ≥ = 70 % Adequate bone marrow function : absolute neutrophil count ≥ = 1,500/μl , platelet ≥ = 100,000/μl , hemoglobin ≥ = 9 gm/dl Adequate hepatic function : Total Bilirubin ≤ = institutional upper limit normal ( ULN ) AST ALT Alkaline Phosphatase must within range allow eligibility . In determine eligibility abnormal two value ( AST ALT ) use Patients must adequate renal function : serum creatinine ≤ 1.5 mg/dl estimate creatinine clearance ≥ 45 ml/min Cockcroft Gault method Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter Women childbearing potential must negative pregnancy test Patients must ability understand willingness sign write informed consent document Other active malignancy , indolent malignancy investigator determines unlikely interfere treatment efficacy analysis . For example , patient nonmelanoma skin cancer , situ carcinoma cervix , prostate cancer within current biochemical ( PSA ) radiologic evidence disease may enroll Prior radiation therapy head neck cancer Patients multifocal peripheral sensory alteration paresthesias ( include tingle ) interfere function , per patient report ( example : activity daily live ) Inability comply study and/or followup procedure Women pregnant lactate Serious concomitant medical disorder ( example , active infection , uncontrolled seizure disorder , unstable angina , autoimmune connective tissue disease ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study History severe infusion reaction monoclonal antibody Patients nasopharyngeal carcinoma eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MAB C225 ( CETUXIMAB ) ( ANTI-EGFR )</keyword>
	<keyword>TAXOL ( PACLITAXEL )</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>08-084</keyword>
</DOC>